Details
| Stereochemistry | MIXED |
| Molecular Formula | C38H56O7 |
| Molecular Weight | 624.847 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O)OC(=O)C6CCCCC6C(O)=O
InChI
InChIKey=IPIHZIYZLLMCRF-ZTDUETTNSA-N
InChI=1S/C38H56O7/c1-33(2)27-12-15-38(7)29(36(27,5)14-13-28(33)45-31(42)23-11-9-8-10-22(23)30(40)41)26(39)20-24-25-21-35(4,32(43)44)17-16-34(25,3)18-19-37(24,38)6/h20,22-23,25,27-29H,8-19,21H2,1-7H3,(H,40,41)(H,43,44)/t22?,23?,25-,27-,28-,29+,34+,35-,36-,37+,38+/m0/s1
Cicloxolone is a broad spectrum antiviral agent with a largely non-specific and complex mode of antiviral action. The drug was active during all stages of the virus replication cycle, indicating that it does not operate by the specific inhibition of any single essential virus gene product. The drug reduced the number of vesicular stomatitis virusparticles assembled and released by 100- to 1000-fold. Infectious virus yield was reduced 1000- to 10000-fold, giving a 10-fold or greater increase in the particle/p.f.u. ratio. The reduced number of virus particles produced in the presence of Cicloxolone results from two superimposed effects: suppression of vesicular stomatitis virussecondary transcription and viral protein synthesis, and perturbation of virion assembly.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3798
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
3F85I03NLO
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106051
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
52247-86-6
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
SUB06254MIG
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
C63946
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
100000081307
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
86278249
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
DTXSID601023744
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY | |||
|
C041842
Created by
admin on Mon Mar 31 18:20:53 GMT 2025 , Edited by admin on Mon Mar 31 18:20:53 GMT 2025
|
PRIMARY |
ACTIVE MOIETY